SEC Tracker
Get the app

Palvella Therapeutics PVLA

Palvella Therapeutics, Inc. announced its financial results for the year ended December 31

Form
8-K
Filed
Importance
Routine
  • Reports quarterly results (2.02)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Palvella Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Tvardi Therapeutics TVRD public float $207M, Jun 30, 2025
  2. Natures Sunshine Products NATR public float $211M, Jun 30, 2025
  3. Rocket Pharmaceuticals RCKT public float $213M, Jun 30, 2025
  4. Perspective Therapeutics CATX public float $213M, Jun 30, 2025
  5. Crescent Biopharma CBIO public float $177M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.